Publikationsserver der Universitätsbibliothek Marburg
Titel:Development of new inhibitors for the type II transmembrane serine protease matriptase
Autor:Hammami Maya
Weitere Beteiligte: Steinmetzer, Torsten (Prof. Dr.)
Veröffentlicht:2012
URI:https://archiv.ub.uni-marburg.de/diss/z2012/0955
DOI: https://doi.org/10.17192/z2012.0955
URN: urn:nbn:de:hebis:04-z2012-09556
DDC: Naturwissenschaften
Titel (trans.):Entwicklung neuer Hemmstoffe der Typ II transmembranären Serinprotease Matriptase.
Publikationsdatum:2012-11-16
Lizenz:https://rightsstatements.org/vocab/InC-NC/1.0/

Dokument

Schlagwörter:
Matriptase, H9N2 influenza virus, Cancer, Influenza, Inhibitors, Matriptase, Serinprotease, Cancer, Matriptase

Summary:
Several new inhibitors were prepared and tested as potential matriptase inhibitors. The most potent compounds were found among the tertiary amides of arylsulfonylated-3-amidinophenylalanines. The incorporation of suitable bis-substituted biphenylsulfonyl groups in combination with appropriate C-terminal urea structures provided the final strong potent monobasic matriptase inhibitors with acceptable selectivity against related trypsin-like serine proteases. Such compounds are suitable candidates for their further evaluation in cell culture experiments to elucidate the potential role of matriptase in pathophysiological processes

Bibliographie / References

  1. Catalona, M. A. Watson, J. Milbrandt, Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001, 61(15), 5692-5696.
  2. J. C. Powers, J. L. Asgian, O. D. Ekici, K. E. James, Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem Rev 2002, 102(12), 4639-4750.
  3. M. J. Dixon, O. A. Andersen, D. M. van Aalten, I. M. Eggleston, An efficient synthesis of argifin: a natural product chitinase inhibitor with chemotherapeutic potential. Bioorg Med Chem Lett 2005, 15(21), 4717-4721.
  4. T. Steinmetzer, B. Baum, A. Biela, G. Klebe, A. K. G. Nowak, E. Bucha, Beyond Heparinization: Design of highly potent thrombin inhibitors suitable for surface coupling. ChemMedChem 2012(submitted).
  5. K. List, J. P. Hobson, A. Molinolo, T. H. Bugge, Co-localization of the channel activating protease prostasin/(CAP1/PRSS8) with its candidate activator, matriptase. J Cell Physiol 2007, 213(1), 237-245.
  6. R. W. Jubb, H. B. Fell, The breakdown of collagen by chondrocytes. J Pathol 1980, 130(3), 159-167.
  7. V. J. Kidd, J. M. Lahti, T. Teitz, Proteolytic regulation of apoptosis. Semin Cell Dev Biol 2000, 11(3), 191-201.
  8. P. Anand, A. B. Kunnumakara, C. Sundaram, K. B. Harikumar, S. T. Tharakan, O. S. Lai, B. Y. Sung, B. B. Aggarwal, Cancer is a Preventable Disease that Requires Major Lifestyle Changes. Pharm Res-Dord 2008, 25(9), 2097-2116.
  9. P. M. Elias, Epidermal barrier function: intercellular lamellar lipid structures, origin, composition and metabolism. J. Controlled Release 1991, 15(3), 199-208.
  10. Ono, T. Esaki, H. Sato, Y. Watanabe, S. Itoh, M. Ohta, T. Kozono, Structure-based design of P3 moieties in the peptide mimetic factor VIIa inhibitor. Biochem Biophys Res Commun 2005, 327(2), 589-596.
  11. T. Shiraishi, S. Kadono, M. Haramura, H. Kodama, Y. Ono, H. Iikura, T. Esaki, T. Koga, K. Hattori, Y. Watanabe, A. Sakamoto, K. Yoshihashi, T. Kitazawa, K. Esaki, M. Ohta, H. Sato, T. Kozono, Factor VIIa inhibitors: target hopping in the serine protease family using X-ray structure determination. Bioorg Med Chem Lett 2008, 18(16), 4533-4537.
  12. L. Silvestri, A. Pagani, A. Nai, I. De Domenico, J. Kaplan, C. Camaschella, The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008, 8(6), 502-511.
  13. C. J. Farady, J. Sun, M. R. Darragh, S. M. Miller, C. S. Craik, The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1). J Mol Biol 2007, 369(4), 1041-1051. References 167
  14. B. Fan, J. Brennan, D. Grant, F. Peale, L. Rangell, D. Kirchhofer, Hepatocyte growth factor activator inhibitor-1 (HAI-1) is essential for the integrity of basement membranes in the developing placental labyrinth. Dev Biol 2007, 303(1), 222-230.
  15. Fliegl, W. Klopper, J. V. Naubron, T. T. Bui, A. F. Drake, C. Roussel, Ridge-tile-like chiral topology: synthesis, resolution, and complete chiroptical characterization of enantiomers of edge-sharing binuclear square planar complexes of Ni(II) bearing achiral ligands. J Am Chem Soc 2010, 132(30), 10477-10483.
  16. Mahler, L. Brady, K. Wilkinson, PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors. J Med Chem 2002, 45(6), 1221-1232.
  17. Matthews, R. McMenamin, D. M. Smith, M. Vinkovic, N. G. Wallis, Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem 2008, 51(2), 183-186.
  18. Hennies, Ichthyosis, Follicular Atrophoderma, and Hypotrichosis Caused by Mutations in ST14 Is Associated with Impaired Profilaggrin Processing. J Invest Dermatol 2008.
  19. T. C. Scharschmidt, K. List, E. A. Grice, R. Szabo, N. C. S. Program, G. Renaud, C. C. Lee, T. G. Wolfsberg, T. H. Bugge, J. A. Segre, Matriptase-Deficient Mice Exhibit Ichthyotic Skin with a Selective Shift in Skin Microbiota. J Invest Dermatol 2009.
  20. A. C. Riddick, C. J. Shukla, C. J. Pennington, R. Bass, R. K. Nuttall, A. Hogan, K. K. Sethia, V. Ellis, A. T. Collins, N. J. Maitland, R. Y. Ball, D. R. Edwards, Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer 2005, 92(12), 2171-2180.
  21. Steinmetzer, New 3-amidinophenylalanine-derived inhibitors of matriptase. MedChemComm 2012(3), 807-813.
  22. I. A. Khatri, R. Wang, J. F. Forstner, SEA (sea-urchin sperm protein, enterokinase and agrin)-module cleavage, association of fragments and membrane targeting of rat intestinal mucin Muc3. Biochem J 2003, 372(Pt 1), 263-270.
  23. R. Szabo, S. Netzel-Arnett, J. P. Hobson, T. M. Antalis, T. H. Bugge, Matriptase- 3 is a novel phylogenetically preserved membrane-anchored serine protease with broad serpin reactivity. Biochem J 2005, 390(Pt 1), 231-242.
  24. A. S. Bhatt, A. Welm, C. J. Farady, M. Vasquez, K. Wilson, C. S. Craik, Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proc Natl Acad Sci U S A 2007, 104(14), 5771-5776.
  25. M. Antalis, T. H. Bugge, K. List, Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J Biol Chem 2006, 281(44), 32941-32945.
  26. J. E. Maxson, J. Chen, C. A. Enns, A. S. Zhang, Matriptase-2-and proprotein convertase-cleaved forms of hemojuvelin have different roles in the down-regulation of hepcidin expression. J Biol Chem 2010, 285(50), 39021-39028.
  27. G. Marino, J. A. Uria, X. S. Puente, V. Quesada, J. Bordallo, C. Lopez-Otin, Human autophagins, a family of cysteine proteinases potentially implicated in cell degradation by autophagy. J Biol Chem 2003, 278(6), 3671-3678.
  28. Bugge, Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1. J Cell Biol 2003, 163(4), 901-910. References 163
  29. X. Jin, M. Yagi, N. Akiyama, T. Hirosaki, S. Higashi, C. Y. Lin, R. B. Dickson, H. Kitamura, K. Miyazaki, Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci 2006, 97(12), 1327-1334. References 161
  30. Jin, Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters. Dis Esophagus 2006, 19(6), 482-486.
  31. O'Brien, Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumour Biol 2001, 22(2), 104-114.
  32. Sieuwerts, M. Timmermans, V. Magdolen, M. Schmitt, J. G. M. Klijn, J. A. Foekens, Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb. Haemostasis 2005, 93(4), 779-786.
  33. I. Seitz, S. Hess, H. Schulz, R. Eckl, G. Busch, H. P. Montens, R. Brandl, S. Seidl, A. Schomig, I. Ott, Membrane-type serine protease-1/matriptase induces interleukin-6 and -8 in endothelial cells by activation of protease-activated receptor-2: potential implications in atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27(4), 769-775.
  34. Astudillo, T. Bernal, R. Cabanillas, C. Lopez-Otin, G. Velasco, Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. Blood 2008, 112(6), 2539-2545.
  35. C. Yuan, L. Chen, E. J. Meehan, N. Daly, D. J. Craik, M. Huang, J. C. Ngo, Structure of catalytic domain of Matriptase in complex with Sunflower trypsin inhibitor-1. BMC Struct Biol 2011, 11, 30.
  36. C. Boileau, N. Amiable, J. Martel-Pelletier, H. Fahmi, N. Duval, J. P. Pelletier, Activation of proteinase-activated receptor 2 in human osteoarthritic cartilage upregulates catabolic and proinflammatory pathways capable of inducing cartilage degradation: a basic science study. Arthritis Res Ther 2007, 9(6), R121.
  37. M. Sienczyk, J. Oleksyszyn, Irreversible inhibition of serine proteases -design and in vivo activity of diaryl alpha-aminophosphonate derivatives. Curr Med Chem 2009, 16(13), 1673-1687.
  38. K. List, R. Szabo, A. Molinolo, B. S. Nielsen, T. H. Bugge, Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis. Am J Pathol 2006, 168(5), 1513-1525.
  39. K. List, P. Kosa, R. Szabo, A. L. Bey, C. B. Wang, A. Molinolo, T. H. Bugge, Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway. Am J Pathol 2009, 175(4), 1453-1463.
  40. L. Zeng, J. Cao, X. Zhang, Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J Gastroenterol 2005, 11(39), 6202-6207. References 165
  41. D. Förbs, S. Thiel, M. C. Stella, A. Stürzebecher, A. Schweinitz, T. Steinmetzer, J. Stürzebecher, K. Uhland, In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol 2005, 27(4), 1061-1070.
  42. -(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5- yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005, 48(19), 5900-5908.
  43. D. M. Krein, T. L. Lowary, A convenient synthesis of 2-(alkylamino)pyridines. J Org Chem 2002, 67(14), 4965-4967.
  44. J. M. Milner, S. F. Elliott, T. E. Cawston, Activation of procollagenases is a key control point in cartilage collagen degradation: interaction of serine and metalloproteinase pathways. Arthritis Rheum 2001, 44(9), 2084-2096.
  45. Obst-Sander, B. Wagner, M. Kansy, F. Diederich, A fluorine scan at the catalytic center of thrombin: C--F, C--OH, and C--OMe bioisosterism and fluorine effects on pKa and log D values. ChemMedChem 2006, 1(6), 611-621.
  46. Madison, D. B. Agus, CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate 2004, 61(3), 228-235.
  47. M. de Candia, G. Lopopolo, C. Altomare, Novel factor Xa inhibitors: a patent review. Expert Opin Ther Pat 2009, 19(11), 1535-1580.
  48. G. Blotny, A new, mild preparation of sulfonyl chlorides. Tetrahedron Letters 2003, 44(7), 1499-1501.
  49. Gotley, J. P. Quigley, T. M. Antalis, Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb Haemost 2003, 89(3), 561-572.
  50. J. D. Hooper, J. A. Clements, J. P. Quigley, T. M. Antalis, Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem 2001, 276(2), 857-860.
  51. J. C. Sheehan, J. Preston, Cruicksh.Pa, A Rapid Synthesis of Oligopeptides Derivates without Isolation of Intermediates. Journal of the American Chemical Society 1965, 87(11), 2492-&. References 175
  52. H. Sajiki, T. Ikawa, K. Hattori, K. Hirota, A remarkable solvent effect toward the Pd/C-catalyzed cleavage of silyl ethers. Chem Commun (Camb) 2003(5), 654-655.
  53. S. Satomi, Y. Yamasaki, S. Tsuzuki, Y. Hitomi, T. Iwanaga, T. Fushiki, A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover. Biochem Biophys Res Commun 2001, 287(4), 995-1002.
  54. Sprecher, M. Shohat, Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase. Am J Hum Genet 2007, 80(3), 467-477.
  55. B. D. Judkins, Allen, D. G., Cook, T. A., Evans, B., Sardharwala, T. E., A versatile synthesis of amidines from nitriles via amidoximes. Synthetic Communications 1996, 26,, 4351-4367.
  56. F. Blasi, P. Carmeliet, uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002, 3(12), 932-943.
  57. Behm, A. T. Look, J. M. Lahti, V. J. Kidd, Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000, 6(5), 529-535. References 155
  58. G. S. Salvesen, Caspases and apoptosis. Proteases in Biology and Medicine 2002, 38, 9-19.
  59. Raitano, A. Jakobovits, Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res 2001, 61(4), 1686-1692.
  60. Pierson, R. Gonzalez, R. Huber, W. Bode, E. L. Madison, Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase. J Biol Chem 2002, 277(3), 2160-2168.
  61. J. B. Konopka, S. M. Watanabe, J. W. Singer, S. J. Collins, O. N. Witte, Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. Proc Natl Acad Sci U S A 1985, 82(6), 1810-1814.
  62. T. Takeuchi, J. L. Harris, W. Huang, K. W. Yan, S. R. Coughlin, C. S. Craik, Cellular localization of membrane-type serine protease 1 and identification of protease- activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000, 275(34), 26333-26342.
  63. C. Y. Lin, J. K. Wang, J. Torri, L. Dou, Q. A. Sang, R. B. Dickson, Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization.
  64. Shortridge, R. G. Webster, Y. Guan, Characterization of H9 subtype influenza viruses from the ducks of southern China: a candidate for the next influenza pandemic in humans? J Virol 2003, 77(12), 6988-6994.
  65. S. Fortin, E. Moreau, J. Lacroix, J. C. Teulade, A. Patenaude, C. G. R, N-Phenyl- N'-(2-chloroethyl)urea analogues of combretastatin A-4: Is the N-phenyl-N'-(2- chloroethyl)urea pharmacophore mimicking the trimethoxy phenyl moiety? Bioorganic & medicinal chemistry letters 2007, 17(7), 2000-2004.
  66. Gleitz, J. Marz, C. Tsaklakidis, Chlorothiophenecarboxamides as P1 surrogates of References 172 inhibitors of blood coagulation factor Xa. Bioorg Med Chem Lett 2004, 14(23), 5817- 5822.
  67. H. Betsunoh, S. Mukai, Y. Akiyama, T. Fukushima, N. Minamiguchi, Y. Hasui, Y. Osada, H. Kataoka, Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci 2007, 98(4), 491-498.
  68. M. G. Kim, C. Chen, M. S. Lyu, E. G. Cho, D. Park, C. Kozak, R. H. Schwartz, Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics 1999, 49(5), 420-428.
  69. Leonard, S. I. Ho, Q. Y. Wu, W. Post, M. H. Drazner, Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation 2005, 112(16), 2403-2410.
  70. Stürzebecher, U. Jacob, Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure- based drug design. J Mol Biol 2000, 301(2), 465-475.
  71. Weaver, S. S. Abdel-Meguid, J. E. Strickler, Crystal structures of the FXIa catalytic domain in complex with ecotin mutants reveal substrate-like interactions. J Biol Chem 2005, 280(6), 4704-4712.
  72. C. Jedeszko, B. F. Sloane, Cysteine cathepsins in human cancer. Biol Chem 2004, 385(11), 1017-1027.
  73. Kurachi, K. J. Pienta, M. A. Rubin, A. M. Chinnaiyan, Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412(6849), 822-826.
  74. C. M. Benaud, M. Oberst, R. B. Dickson, C. Y. Lin, Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis 2002, 19(7), 639-649.
  75. Krueger, C. M. Cooper, J. P. Vacca, Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. J Med Chem 1998, 41(17), 3210-3219.
  76. Michejda, P. P. Roller, Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-
  77. Dunwiddie, R. J. Leadley, Design of a new class of orally active fibrinogen receptor antagonists. J Med Chem 1998, 41(14), 2492-2502.
  78. Naylor-Olsen, S. D. Lewis, B. J. Lucas, J. P. Vacca, Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure- activity studies by solid-phase synthesis. J Med Chem 1998, 41(7), 1011-1013.
  79. Garten, T. Steinmetzer, Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT. Bioorg Med Chem Lett 2011, 21(16), 4860-4864.
  80. Zhu, Y. Huang, Y. Q. Long, P. P. Roller, D. Yang, S. Wang, Discovery of small- molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 2001, 44(25), 4313-4324.
  81. A. F. Chambers, A. C. Groom, I. C. MacDonald, Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2(8), 563-572.
  82. L. Moroder, A. Hallett, E. Wunsch, O. Keller, G. Wersin, [Di-tert.-butyl- dicarbonate, a useful tert.-Butyloxycardonylating reagent (author's transl)]. Hoppe Seylers Z Physiol Chem 1976, 357(11), 1651-1653.
  83. P. M. Comoglio, S. Giordano, L. Trusolino, Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008, 7(6), 504- 516.
  84. S. Q. Yang, C. I. Wang, S. A. Gillmor, R. J. Fletterick, C. S. Craik, Ecotin: a serine protease inhibitor with two distinct and interacting binding sites. Journal of molecular biology 1998, 279(4), 945-957.
  85. Yoneda, S. Yasuoka, S. Sone, Effect of human airway trypsin-like protease on intracellular free Ca2+ concentration in human bronchial epithelial cells. The journal of medical investigation : JMI 2003, 50(1-2), 95-107.
  86. H. Wenschuh, M. Beyermann, E. Krause, L. A. Carpino, M. Bienert, Efficient Solid-Phase Assembly of Peptides Bearing Contiguous Highly Hindered Aib Residues Via Fmoc Aib Fluoride. Tetrahedron Lett 1993, 34(23), 3733-3736. [235] L. A. Carpino, A. Elfaham, Tetramethylfluoroformamidinium Hexafluorophosphate -a Rapid-Acting Peptide Coupling Reagent for Solution and Solid-Phase Peptide-Synthesis. Journal of the American Chemical Society 1995, 117(19), 5401-5402.
  87. C. Lopez-Otin, L. M. Matrisian, Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007, 7(10), 800-808.
  88. J. M. Milner, A. Patel, A. D. Rowan, Emerging roles of serine proteinases in tissue turnover in arthritis. Arthritis Rheum 2008, 58(12), 3644-3656.
  89. Mackman, Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets. Chem Biol 2001, 8(11), 1107-1121.
  90. Y. Kitamoto, X. Yuan, Q. Wu, D. W. McCourt, J. E. Sadler, Enterokinase, the initiator of intestinal digestion, is a mosaic protease composed of a distinctive assortment of domains. Proc Natl Acad Sci U S A 1994, 91(16), 7588-7592.
  91. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, D. M. Parkin, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12), 2893-2917.
  92. Y. Adachi, F. Itoh, H. Yamamoto, Y. Arimura, Y. Kikkawa-Okabe, K. Miyazaki, D. P. Carbone, K. Imai, Expression of angiomodulin (tumor-derived adhesion factor/mac25) in invading tumor cells correlates with poor prognosis in human colorectal cancer. Int J Cancer 2001, 95(4), 216-222.
  93. Williams, A. al-Nafussi, J. F. Smyth, H. Gabra, G. C. Sellar, Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 2002, 8(4), 1101-1107.
  94. S. Watson, H. E. Weston, C. Whitworth, R. J. Young, P. Zhou, Factor Xa inhibitors: S1 References 170 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2- oxoethyl]-2-oxopyrrolidin-3-yl }sulfonamides. J Med Chem 2007, 50(7), 1546-1557.
  95. S. Yoshinaga, Y. Nakahori, S. Yasuoka, Fibrinogenolytic activity of a novel trypsin-like enzyme found in human airway. J Med Invest 1998, 45(1-4), 77-86.
  96. Shaughnessy, Jr., S. Pecorelli, Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 2004, 112(1), 14-25.
  97. P. Auffinger, F. A. Hays, E. Westhof, P. S. Ho, Halogen bonds in biological molecules. Proc Natl Acad Sci U S A 2004, 101(48), 16789-16794.
  98. W. W. Mederski, D. Dorsch, S. Anzali, J. Gleitz, B. Cezanne, C. Tsaklakidis, Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa. Bioorg Med Chem Lett 2004, 14(14), 3763-3769.
  99. Choe, C. S. Craik, N. Walker, D. Meininger, T. Hoey, R. J. Austin, Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J 2005, 390(Pt 1), 125- 136.
  100. Garabaya, C. Lopez-Otin, Identification and characterization of human polyserase-3, a novel protein with tandem serine-protease domains in the same polypeptide chain. BMC Biochem 2006, 7, 9.
  101. H. S. Kim, S. R. Nagalla, Y. Oh, E. Wilson, C. T. Roberts, Jr., R. G. Rosenfeld, Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): characterization of connective tissue growth factor as a member of the IGFBP superfamily. Proc Natl Acad Sci U S A 1997, 94(24), 12981-12986.
  102. Dickson, K. Miyazaki, Identification of membrane-bound serine proteinase matriptase as processing enzyme of insulin-like growth factor binding protein-related protein-1
  103. M. T. Sisay, T. Steinmetzer, M. Stirnberg, E. Maurer, M. Hammami, J. Bajorath, M. Gutschow, Identification of the first low-molecular-weight inhibitors of matriptase-
  104. (IGFBP-rP1/angiomodulin/mac25). FEBS J 2006, 273(3), 615-627.
  105. A. Schweinitz, D. Dönnecke, A. Ludwig, P. Steinmetzer, A. Schulze, J. Kotthaus, S. Wein, B. Clement, T. Steinmetzer, Incorporation of neutral C-terminal residues in 3- References 169 amidinophenylalanine-derived matriptase inhibitors. Bioorg Med Chem Lett 2009, 19(7), 1960-1965.
  106. J. S. Jin, D. S. Hsieh, S. H. Loh, A. Chen, C. W. Yao, C. Y. Yen, Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Mod Pathol 2006, 19(3), 447-452.
  107. S. Bajusz, E. Barabas, P. Tolnay, E. Szell, D. Bagdy, Inhibition of thrombin and trypsin by tripeptide aldehydes. Int J Pept Protein Res 1978, 12(4), 217-221.
  108. J. I. Jones, D. R. Clemmons, Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995, 16(1), 3-34.
  109. A. Biela, F. Sielaff, F. Terwesten, A. Heine, T. Steinmetzer, G. Klebe, Ligand binding gradually disrupts water network in thrombin: Enthalpic and entropic changes reveal classical hydrophobic effect. J Med Chem 2012.
  110. S. Cal, V. Quesada, C. Garabaya, C. Lopez-Otin, Polyserase-I, a human polyprotease with the ability to generate independent serine protease domains from a single translation product. Proc Natl Acad Sci U S A 2003, 100(16), 9185-9190.
  111. G. Velasco, S. Cal, V. Quesada, L. M. Sanchez, C. Lopez-Otin, Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins. J Biol Chem 2002, 277(40), 37637-37646.
  112. C. Parr, A. J. Sanders, G. Davies, T. Martin, J. Lane, M. D. Mason, R. E. Mansel, W. G. Jiang, Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients. Clin Cancer Res 2007, 13(12), 3568- 3576.
  113. K. Uhland, Matriptase and its putative role in cancer. Cell Mol Life Sci 2006, 63(24), 2968-2978.
  114. R. Szabo, A. Molinolo, K. List, T. H. Bugge, Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development. Oncogene 2007, 26(11), 1546-1556.
  115. Lockhart, R. Leduc, A. D. Rowan, Matriptase is a novel initiator of cartilage matrix degradation in osteoarthritis. Arthritis Rheum 2010, 62(7), 1955-1966.
  116. Engelholm, N. Behrendt, T. H. Bugge, Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 2002, 21(23), 3765-3779.
  117. L. M. Coussens, B. Fingleton, L. M. Matrisian, Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295(5564), 2387-2392.
  118. T. M. Antalis, T. H. Bugge, Q. Wu, Membrane-anchored serine proteases in health and disease. Prog Mol Biol Transl Sci 2011, 99, 1-50.
  119. M. Goodman, Felix, A., Moroder, L, Toniolo, C. (Eds.) Methods of Organic Chemistry, (Houben-Weyl), in Additional and Supplementary Volumes to the 4 th Edition, Synthesis of Peptides and Peptidomimetics, Vol. Vol. E 22a-e, Georg Thieme Verlag Stuttgart New York, 2004.
  120. Schulze, S. M. Saupe, A. Schweinitz, Modification of the N-terminal sulfonyl residue in 3-amidinophenylalanine-based matriptase inhibitors. Bioorg Med Chem Lett 2009, 19(1), 67-73.
  121. C. Y. Lin, J. Anders, M. Johnson, Q. A. Sang, R. B. Dickson, Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem 1999, 274(26), 18231-18236.
  122. Quigley, Mouse matriptase-2: identification, characterization and comparative mRNA expression analysis with mouse hepsin in adult and embryonic tissues. Biochem J 2003, 373(Pt 3), 689-702.
  123. Eady, E. A. O'Toole, Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis. Am J Hum Genet 2005, 76(5), 794-803.
  124. D. Fleming, Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008, 40(5), 569-571.
  125. Vande Woude, Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A 2001, 98(13), 7443-7448.
  126. M. Egeblad, Z. Werb, New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2(3), 161-174.
  127. Steinmetzer, New substrate analogue inhibitors of factor Xa containing 4- amidinobenzylamide as P1 residue: part 1. Med Chem 2006, 2(4), 349-361.
  128. K. Matsumoto, T. Nakamura, NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 2003, 94(4), 321-327.
  129. K. Lee, W. H. Jung, M. Kang, S. H. Lee, Noncovalent thrombin inhibitors incorporating an imidazolylethynyl P1. Bioorg Med Chem Lett 2000, 10(24), 2775- 2778.
  130. T. Steinmetzer, G. Nowak, Oligo or polyalkylene glycol-coupled thrombin inhibitors, (Haemosys Gmbh, Germany). Application: WO WO, 2002, p. 58 pp. Publications 177
  131. C. M. Croce, Oncogenes and cancer. N Engl J Med 2008, 358(5), 502-511.
  132. P. Walsmann, [On the purification of thrombin preparations]. Pharmazie 1968, 23(7), 401-402.
  133. G. R. Cousins, G. S. Friedrichs, Y. Sudo, S. S. Rebello, W. E. Rote, G. P. Vlasuk, T. G. Nolan, C. Mendoza, B. R. Lucchesi, Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog. Circulation 1996, 94(7), 1705-1712.
  134. Wang, T. H. Parmley, T. J. O'Brien, Ovarian tumor cells express a novel multi-domain cell surface serine protease. Biochim Biophys Acta 2000, 1502(3), 337-350.
  135. C. C. Sprenger, M. E. Vail, K. Evans, J. Simurdak, S. R. Plymate, Over- expression of insulin-like growth factor binding protein-related protein-1(IGFBP- rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis. Oncogene 2002, 21(1), 140-147.
  136. M. Matrosovich, T. Matrosovich, J. Carr, N. A. Roberts, H. D. Klenk, Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 2003, 77(15), 8418-8425.
  137. C. M. Brown, M. Ray, A. A. Eroy-Reveles, P. Egea, C. Tajon, C. S. Craik, Peptide length and leaving-group sterics influence potency of peptide phosphonate protease inhibitors. Chemistry & biology 2011, 18(1), 48-57.
  138. Urmann, K. Ritter, M. Wagner, V. Wehner, Evidence for C-Cl/C-Br...pi interactions as an important contribution to protein-ligand binding affinity. Angewandte Chemie (International ed in English) 2009, 48(16), 2911-2916.
  139. J. Sun, J. Pons, C. S. Craik, Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies. Biochemistry 2003, 42(4), 892-900.
  140. M. Lahti, D. A. Cheresh, Potentiation of neuroblastoma metastasis by loss of caspase-8.
  141. Maruyama, M. Sugano, Y. Tamao, Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981, 101(2), 440- 446.
  142. W. Stüber, R. Koschinsky, M. Reers, D. Hoffmann, J. Czech, G. Dickneite, Preparation and evaluation of PEG-bound thrombin inhibitors based on 4- amidinophenylalanine. Pept Res 1995, 8(2), 78-85.
  143. Semple, A. P. Tamiz, Preparation of matriptase inhibitors for the treatment of cancer, (Dendreon Corporation, USA). WO 2004/058688 2004.
  144. J. L. Boivin, P. A. Boivin, Preparation of N-substituted ureas from nitrosomethylureas. Canadian journal of chemistry 1951, 29(6), 478-481.
  145. Ong, G. L. Araldi, Preparation of peptides as inhibitors of serine protease activity of matriptase or MTSP1, (Corvas International, Inc., USA). WO 02/20475 2002.
  146. T. Steinmetzer, A. Schweinitz, D. Dönnecke, Preparation of phenylsulfonyl amides as antitumor agents, (Curacyte Discovery GmbH, Germany). Application: WO WO, 2008, p. 68pp.
  147. F. Wu, W. Yan, J. L. Pan, J. Morser, Q. Y. Wu, Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. Journal of Biological Chemistry 2002, 277(19), 16900-16905.
  148. Savolainen, Prodrugs: design and clinical applications. Nat Rev Drug Discov 2008, 7(3), 255-270.
  149. L. M. Chen, K. X. Chai, Prostasin serine protease inhibits breast cancer invasiveness and is transcriptionally regulated by promoter DNA methylation. Int J Cancer 2002, 97(3), 323-329.
  150. X. Shi, B. Gangadharan, L. F. Brass, W. Ruf, B. M. Mueller, Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004, 2(7), 395-402.
  151. P. J. O'Brien, M. Molino, M. Kahn, L. F. Brass, Protease activated receptors: theme and variations. Oncogene 2001, 20(13), 1570-1581.
  152. S. Ihara, E. Miyoshi, N. Taniguchi, [Protease modified by sugar chain: beta 1-6 branching and matriptase]. Tanpakushitsu Kakusan Koso 2003, 48(8 Suppl), 980-983.
  153. W. Ge, H. Hu, K. Ding, L. Sun, S. Zheng, Protein interaction analysis of ST14 domains and their point and deletion mutants. J Biol Chem 2006, 281(11), 7406-7412.
  154. P. Moran, W. Li, B. Fan, R. Vij, C. Eigenbrot, D. Kirchhofer, Pro-urokinase-type plasminogen activator is a substrate for hepsin. J Biol Chem 2006, 281(41), 30439- 30446.
  155. C. Y. Lin, J. Anders, M. Johnson, R. B. Dickson, Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999, 274(26), 18237-18242.
  156. C. H. Chung, H. E. Ives, S. Almeda, A. L. Goldberg, Purification from Escherichia coli of a periplasmic protein that is a potent inhibitor of pancreatic proteases. The Journal of biological chemistry 1983, 258(18), 11032-11038.
  157. S. Y. Han, Y. A. Kim, Recent development of peptide coupling reagents in organic synthesis. Tetrahedron 2004, 60(11), 2447-2467.
  158. Dahiya, T. Usui, Restoration of insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through induction of apoptosis in human prostate cancer. Cancer Res 2003, 63(22), 7717-7723.
  159. A. McMahon, I. A. Butovich, N. L. Mata, M. Klein, R. Ritter, 3rd, J. Richardson, D. G. Birch, A. O. Edwards, W. Kedzierski, Retinal pathology and skin barrier defect in mice carrying a Stargardt disease-3 mutation in elongase of very long chain fatty acids-
  160. L. Trusolino, P. M. Comoglio, Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002, 2(4), 289-300.
  161. Schuster, P. Steinmetzer, F. Müller, R. Friedrich, M. E. Than, W. Bode, J. Stürzebecher, Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem 2006, 49(14), 4116-4126.
  162. Y. Okumura, M. Hayama, E. Takahashi, M. Fujiuchi, A. Shimabukuro, M. Yano, H. Kido, Serase-1B, a new splice variant of polyserase-1/TMPRSS9, activates References 157 urokinase-type plasminogen activator and the proteolytic activation is negatively regulated by glycosaminoglycans. The Biochemical journal 2006, 400(3), 551-561.
  163. Herault, C. Lecoffre, C. Pfersdorff, J. M. Herbert, S. E. O'Connor, SSR182289A, a References 171 novel, orally active thrombin inhibitor: in vitro profile and ex vivo anticoagulant activity. J Pharmacol Exp Ther 2002, 303(3), 1189-1198.
  164. R. E. Steiger, dl-a-Amino-a-phenylpropionic acid (dl-Alanine, a-phenyl-). Org Synth 1944, 24, 9-12.
  165. S. Künzel, A. Schweinitz, S. Reissmann, J. Stürzebecher, T. Steinmetzer, 4- amidinobenzylamine-based inhibitors of urokinase. Bioorg Med Chem Lett 2002, 12(4), 645-648. References 173
  166. Publications A part of this work has been published M. Hammami, E. Rühmann, E. Maurer, A. Heine, M. Gütschow, G. Klebe, T. Steinmetzer; New 3-amidinophenylalanine derived inhibitors of matriptase. MedChemComm, 2012(3), 807- 813.
  167. M. Renatus, W. Bode, R. Huber, J. Stürzebecher, M. T. Stubbs, Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase. J Med Chem 1998, 41(27), 5445-5456.
  168. Kurokawa, K. Tashiro, K. Shiokawa, K. Shinomiya, et al., Structural characterization of porcine enteropeptidase. J Biol Chem 1994, 269(31), 19976-19982.
  169. Stürzebecher, Structure-activity relationships of new NAPAP-analogs. J Enzyme Inhib Med Chem 2002, 17(2), 241-249.
  170. R. T. Shuman, R. B. Rothenberger, C. S. Campbell, G. F. Smith, D. S. Gifford- Moore, J. W. Paschal, P. D. Gesellchen, Structure-activity study of tripeptide thrombin inhibitors using alpha-alkyl amino acids and other conformationally constrained amino acid substitutions. Journal of Medicinal Chemistry 1995, 38(22), 4446-4453.
  171. N. H. Hauel, H. Nar, H. Priepke, U. Ries, J. M. Stassen, W. Wienen, Structure- based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002, 45(9), 1757-1766.
  172. Tebbe, J. M. Tinsley, Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity. J Med Chem 2000, 43(5), 883-899.
  173. M. Zürcher, F. Diederich, Structure-based drug design: exploring the proper filling of apolar pockets at enzyme active sites. J Org Chem 2008, 73(12), 4345-4361.
  174. Huber, D. T. Blankenship, A. D. Cardin, W. Kisiel, Structure of human des(1-45) factor Xa at 2.2 A resolution. J Mol Biol 1993, 232(3), 947-966.
  175. X. Yuan, X. Zheng, D. Lu, D. C. Rubin, C. Y. Pung, J. E. Sadler, Structure of murine enterokinase (enteropeptidase) and expression in small intestine during development. Am J Physiol 1998, 274(2 Pt 1), G342-349.
  176. N. A. Meanwell, Synopsis of some recent tactical application of bioisosteres in drug design. J Med Chem 2011, 54(8), 2529-2591.
  177. H. Brunner, P. Hankofer, B. Treittinger, Synthesis and Antitumor-Activity of Pt(Ii) Complexes of Benzyl-1,2-Diaminoethane Ligands. Chem Ber 1990, 123(5), 1029- 1038.
  178. P. Roller, Synthesis and evaluation of the sunflower derived trypsin inhibitor as a potent inhibitor of the type II transmembrane serine protease, matriptase. Bioorg Med Chem Lett 2001, 11(18), 2515-2519.
  179. H. Matthews, M. Ranson, J. D. Tyndall, M. J. Kelso, Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA). Bioorg Med Chem Lett 2011, 21(22), 6760-6766.
  180. J. Stürzebecher, D. Prasa, J. Hauptmann, H. Vieweg, P. Wikström, Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3- amidinophenylalanine. J Med Chem 1997, 40(19), 3091-3099.
  181. S. Sperl, M. Burgle, W. Schmalix, K. Wosikowski, B. Clement, Synthesis of hydroxyamidine and hydroxyguanidine amino acid or oligopeptide derivatives for use as urokinase plasminogen activator inhibitors for the treatment of cancer and its metastasis, (Wilex A.-G., Germany). Application: WO WO, 2004, p. 48 pp.
  182. S. B. King, B. Ganem, Synthetic Studies on Mannostatin-a and Its Derivatives -a New Family of Glycoprotein Processing Inhibitors. Journal of the American Chemical Society 1994, 116(2), 562-570.
  183. B. Turk, Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006, 5(9), 785-799.
  184. M. D. Oberst, C. A. Williams, R. B. Dickson, M. D. Johnson, C. Y. Lin, The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J Biol Chem 2003, 278(29), 26773-26779.
  185. P. Ascenzi, A. Bocedi, M. Bolognesi, A. Spallarossa, M. Coletta, R. De Cristofaro, E. Menegatti, The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): a milestone protein. Curr Protein Pept Sci 2003, 4(3), 231-251.
  186. Dobson, D. I. Stuart, E. Y. Jones, The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure 1995, 3(7), 681-691.
  187. T. M. Antalis, M. S. Buzza, K. M. Hodge, J. D. Hooper, S. Netzel-Arnett, The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment. Biochem J 2010, 428(3), 325-346.
  188. Mahler, L. Brady, K. Wilkinson, The design of phenylglycine containing benzamidine carboxamides as potent and selective inhibitors of factor Xa. Bioorg Med Chem Lett 2001, 11(5), 733-736.
  189. Sandhoff, E. Hummler, The epidermal barrier function is dependent on the serine protease CAP1/Prss8. J Cell Biol 2005, 170(3), 487-496.
  190. Smorodinsky, D. B. Rubinstein, D. H. Wreschner, The MUC1 SEA module is a self- cleaving domain. J Biol Chem 2005, 280(39), 33374-33386.
  191. Anfossi, J. J. Roman, T. O'Brien, S. Pecorelli, The novel serine protease tumor- associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma. Cancer 2003, 98(9), 1898-1904.
  192. Y. Fang, D. Fu, X. Z. Shen, The potential role of ubiquitin c-terminal hydrolases in oncogenesis. Biochim Biophys Acta 2010, 1806(1), 1-6.
  193. M. Bodanszky, A. Bodanszky, The practice of peptide synthesis, Springer-Verlag, Berlin ; New York, 1994.
  194. Hollenberg, C. P. Sommerhoff, J. S. McLean, W. R. Ferrell, Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation. J Pharmacol Exp Ther 2006, 316(3), 1017-1024.
  195. W. Bode, I. Mayr, U. Baumann, R. Huber, S. R. Stone, J. Hofsteenge, The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 1989, 8(11), 3467-3475.
  196. Mann, E. M. Moresco, E. Beutler, B. Beutler, The serine protease TMPRSS6 is required to sense iron deficiency. Science 2008, 320(5879), 1088-1092. References 159
  197. N. Sidenius, F. Blasi, The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003, 22(2-3), 205-222.
  198. A. Bergner, M. Bauer, H. Brandstetter, J. Sturzebecher, W. Bode, The X-ray crystal structure of thrombin in complex with N alpha-2-naphthylsulfonyl-L-3-amidino- phenylalanyl-4-methylpiperidide: the beneficial effect of filling out an empty cavity. J Enzyme Inhib 1995, 9(1), 101-110.
  199. K. Lee, S. Y. Hwang, C. W. Park, Thrombin inhibitors based on a propargylglycine template. Bioorg Med Chem Lett 1999, 9(7), 1013-1018.
  200. L. Rimm, R. L. Camp, Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003, 63(5), 1101-1105.
  201. R. Szabo, T. H. Bugge, Type II transmembrane serine proteases in development and disease. Int J Biochem Cell Biol 2008, 40(6-7), 1297-1316.
  202. D. Höller, C. M. Hecker, I. Dikic, Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 2006, 6(10), 776-788.
  203. S. Sperl, A. Bergner, J. Sturzebecher, V. Magdolen, W. Bode, L. Moroder, Urethanyl-3-amidinophenylalanine derivatives as inhibitors of factor Xa. X-ray crystal structure of a trypsin/inhibitor complex and modeling studies. Biol Chem 2000, 381(4), 321-329.
  204. Renatus, P. Wikström, 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg Med Chem Lett 1999, 9(21), 3147-3152.
  205. P. Ettmayer, G. L. Amidon, B. Clement, B. Testa, Lessons learned from marketed and investigational prodrugs. J Med Chem 2004, 47(10), 2393-2404.
  206. Stürzebecher, J. Kotthaus, B. Clement, J. Stürzebecher, T. Steinmetzer, Highly potent and selective substrate analogue factor Xa inhibitors containing D-homophenylalanine analogues as P3 residue: part 2. ChemMedChem 2007, 2(7), 1043-1053.
  207. M. Chen, L. M. Chen, K. X. Chai, Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG. Prostate 2006, 66(9), 911-920.
  208. P. Hellstern, U. Stürzebecher, B. Wuchold, H. Haubelt, U. T. Seyfert, M. Bauer, A. Vogt, J. Stürzebecher, Preservation of in vitro function of platelets stored in the presence of a synthetic dual inhibitor of factor Xa and thrombin. J Thromb Haemost 2007, 5(10), 2119-2126.
  209. T. Hashimoto, M. Kato, T. Shimomura, N. Kitamura, TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor. The FEBS journal 2010, 277(23), 4888-4900.
  210. Meroueh, Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis. J Med Chem 2011, 54(20), 7193-7205.
  211. M. S. Bernatowicz, Y. Wu, G. R. Matsueda, 1H-Pyrazole-1-carboxamidine hydrochloride an attractive reagent for guanylation of amines and its application to peptide synthesis. The Journal of Organic Chemistry 1992, 57(8), 2497-2502.
  212. K. Müller, C. Faeh, F. Diederich, Fluorine in pharmaceuticals: looking beyond intuition. Science 2007, 317(5846), 1881-1886.
  213. T. Steinmetzer, J. Stürzebecher, Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants. Curr Med Chem 2004, 11(17), 2297-2321.
  214. S. L. Lee, R. B. Dickson, C. Y. Lin, Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease.
  215. Stürzebecher, Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 2004, 279(32), 33613-33622.
  216. A. Desilets, F. Beliveau, G. Vandal, F. O. McDuff, P. Lavigne, R. Leduc, Mutation G827R in matriptase causing autosomal recessive ichthyosis with hypotrichosis yields an inactive protease. J Biol Chem 2008, 283(16), 10535-10542.
  217. R. Szabo, J. P. Hobson, K. List, A. Molinolo, C. Y. Lin, T. H. Bugge, Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity. J Biol Chem 2008, 283(43), 29495-29504.
  218. Hibino, A. Takeda, Neutral cysteine protease bleomycin hydrolase is essential for the breakdown of deiminated filaggrin into amino acids. J Biol Chem 2009, 284(19), 12829-12836.
  219. M. Comoglio, P. Michieli, An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest 2004, 114(10), 1418-1432.
  220. M. M. Mohamed, B. F. Sloane, Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006, 6(10), 764-775.
  221. D. Gustafsson, R. Bylund, T. Antonsson, I. Nilsson, J. E. Nystrom, U. Eriksson, U. Bredberg, A. C. Teger-Nilsson, A new oral anticoagulant: the 50-year challenge. Nat Rev Drug Discov 2004, 3(8), 649-659.
  222. M. Dixon, The determination of enzyme inhibitor constants. Biochem J 1953, 55(1), 170-171.
  223. E. Böttcher, T. Matrosovich, M. Beyerle, H. D. Klenk, W. Garten, M. Matrosovich, Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J Virol 2006, 80(19), 9896-9898.
  224. Uhlendorff, T. Steinmetzer, H. D. Klenk, W. Garten, Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors. J Virol 2010, 84(11), 5605-5614.
  225. T. Takeuchi, M. A. Shuman, C. S. Craik, Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci U S A 1999, 96(20), 11054-11061.
  226. A. Hoffmann, C. Hetru, A genome-wide analysis of immune responses in Drosophila.
  227. D. Jones, J. L. Olkowski, L. C. Weir, G. F. Smith, D-phe-pro-p-amidinobenzylamine: A potent and highly selective thrombin inhibitor. Bioorganic & Medicinal Chemistry Letters 1996, 6(20), 2387-2392.
  228. H. D. Klenk, W. Garten, Host cell proteases controlling virus pathogenicity. Trends Microbiol 1994, 2(2), 39-43.
  229. E. Frerot, J. Coste, A. Pantaloni, M.-N. Dufour, P. Jouin, PyBop and PyBroP: Two reagents for the difficult coupling of the -dialkyl amino acid, Aib. Tetrahedron 1991, 47(2), 259-270.
  230. E. Böttcher, C. Freuer, T. Steinmetzer, H. D. Klenk, W. Garten, MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition. Vaccine 2009, 27(45), 6324-6329.
  231. Kato, Expression of proteinase-activated receptors (PAR)-2 in articular chondrocytes is modulated by IL-1beta, TNF-alpha and TGF-beta. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2006, 14(11), 1163-1173.

* Das Dokument ist im Internet frei zugänglich - Hinweise zu den Nutzungsrechten
© UB Marburg 1997 - 2024 Universitätsbibliothek Marburg